Access to Tirzepatide (Mounjaro) in Primary Care

Posted by: katiehorton - Posted on:

New community-based weight management services are being developed in the Black Country to support safe and effective access to tirzepatide (Mounjaro), a medication that can help with weight loss and related health conditions.

These will be available via Primary Care from Monday 1st September 2025.

As part of the ICBs phased approach, the first group of patients who may be eligible will include those who:

  • Have a BMI of 40 or more (or 37.5 for people from minority ethnic backgrounds),
  • And have obstructive sleep apnoea on CPAP (or where CPAP is not tolerated)

And have at least three of the following long-term conditions:

  • Type 2 diabetes
  • High blood pressure (hypertension)
  • Cardiovascular disease
  • Dyslipidaemia

Other patients who meet the broader NHS criteria (BMI ≥ 40 and four or more related health conditions) may become eligible in later stages.

For more information please visit; ICB Weight Management page, which will be updated regularly: Weight Management :: Black Country ICB